Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T, Takahashi S, Hiraoka S, Toyokawa T, Takagi S, Takemoto K, Miyaike J, Fujimoto T, Higashi R, Morito Y, Nawa T, Suzuki S, Nishimura M, Inoue M, Kato J, Okada H.
Inokuchi T, et al. Among authors: higashi r.
J Gastroenterol Hepatol. 2019 Aug;34(8):1329-1336. doi: 10.1111/jgh.14624. Epub 2019 Feb 27.
J Gastroenterol Hepatol. 2019.
PMID: 30724387